Priyanka Sharma, Bruce F Kimler, Anne O'Dea, Lauren Nye, Yen Y Wang, Rachel Yoder, Joshua M Staley, Lindsey Prochaska, Jamie Wagner, Amanda L Amin, Kelsey Larson, Christa Balanoff, Manana Elia, Gregory Crane, Sheshadri Madhusudhana, Marc Hoffmann, Maureen Sheehan, Roberto Rodriguez, Karissa Finke, Rajvi Shah, Deepti Satelli, Anuj Shrestha, Larry Beck, Richard McKittrick, Robert Pluenneke, Vinay Raja, Venkatadri Beeki, Larry Corum, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Milind Phadnis, Dinesh Pal Mudaranthakam, Roy A Jensen, Andrew K Godwin, Roberto Salgado, Kathan Mehta, Qamar Khan
PURPOSE: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens. PATIENTS AND METHODS: Patients aged ≥18 years with stage I-III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B)...
February 15, 2021: Clinical Cancer Research